Course: Addressing Adverse Events Associated With Bispecific Antibody Therapies: Managing Care for Patients in Rural and Underserved Communities
CME Credits: 0.00
Released: 2025-09-19
Therapy options using bispecific antibodies (BsAbs) are rapidly expanding and driving improved outcomes across a range of cancers, including both solid tumors and hematologic malignancies. However, patients who reside in rural and underserved communities often encounter significant barriers to multidisciplinary care and may lack the necessary support to manage adverse events associated with treatment. In this on-demand CME/CE activity, expert faculty will review currently available BsAB therapies, outline common treatment-related adverse effects, and highlight recent guideline updates for management. Practical strategies to enhance care and ongoing monitoring for patients on BsAb therapy in rural and underserved settings will also be explored. This enduring activity is a recorded session from Oncology Congress Spring 2025 that took place on June 14, 2025.
		  
			            Upon completion of this activity, participants should be better able to:          
View Full Course